Considerable scale-up is needed to achieve the 2025 goals for HIV pre-exposure prophylaxis (PrEP), according to study findings.

"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Approved by the FDA 12 years ago, pre-exposure prophylaxis (PrEP) has significantly reduced the risk of HIV transmission and ...

A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...

Cidara Therapeutics (CDTX) announced it has reached full planned enrollment of 5,000 subjects in the Phase 2b NAVIGATE trial across clinical ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the ...

But Woodward said the increase could be slowed down if there was greater uptake in drugs that prevent HIV transmission, ...

With new CDC data expressing optimism about the epidemic of sexually transmitted infections (STIs), take a look at the ...

Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves from catching HIV, but according to a new paper in the New England Journal ...

People are at the heart of the HIV pandemic, so it’s important to understand how they make protection decisions.

Recent results from a recent clinical trial indicate that a twice-yearly injection of Lenacapavir offers an overall 96% reduced risk of acquiring HIV. This makes Lenacapavir significantly more ...